Published in Cancer Res on July 15, 2006
Replication and homologous recombination repair regulate DNA double-strand break formation by the antitumor alkylator ecteinascidin 743. Proc Natl Acad Sci U S A (2007) 1.43
BRCA2 is needed for both repair and cell cycle arrest in mammalian cells exposed to S23906, an anticancer monofunctional DNA binder. Cell Cycle (2015) 1.41
Combined modalities of resistance in an oxaliplatin-resistant human gastric cancer cell line with enhanced sensitivity to 5-fluorouracil. Br J Cancer (2007) 0.93
Induction of glutathione-dependent DNA double-strand breaks by the novel anticancer drug brostallicin. Mol Cancer Ther (2009) 0.79
Strategies for the Optimization of Natural Leads to Anticancer Drugs or Drug Candidates. Med Res Rev (2015) 0.78
Protein Recognition in Drug-Induced DNA Alkylation: When the Moonlight Protein GAPDH Meets S23906-1/DNA Minor Groove Adducts. Int J Mol Sci (2015) 0.77
Sterigmatocystin-induced DNA damage triggers G2 arrest via an ATM/p53-related pathway in human gastric epithelium GES-1 cells in vitro. PLoS One (2013) 0.75
Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study. J Clin Oncol (2009) 4.27
The dynamics of actin-based motility depend on surface parameters. Nature (2002) 2.78
Characterization of a large panel of patient-derived tumor xenografts representing the clinical heterogeneity of human colorectal cancer. Clin Cancer Res (2012) 2.04
Replication and homologous recombination repair regulate DNA double-strand break formation by the antitumor alkylator ecteinascidin 743. Proc Natl Acad Sci U S A (2007) 1.43
BRCA2 is needed for both repair and cell cycle arrest in mammalian cells exposed to S23906, an anticancer monofunctional DNA binder. Cell Cycle (2015) 1.41
Epithelial-to-mesenchymal transition and autophagy induction in breast carcinoma promote escape from T-cell-mediated lysis. Cancer Res (2013) 1.36
What histone code for DNA repair? Mutat Res (2008) 1.31
Angiosarcomas and taxanes. Curr Treat Options Oncol (2007) 1.29
Lamellarin D: a novel potent inhibitor of topoisomerase I. Cancer Res (2003) 1.28
Inhibition of Chk1 kills tetraploid tumor cells through a p53-dependent pathway. PLoS One (2007) 1.23
Polo-like kinase 1: a potential therapeutic option in combination with conventional chemotherapy for the management of patients with triple-negative breast cancer. Cancer Res (2012) 1.20
TTK/hMPS1 is an attractive therapeutic target for triple-negative breast cancer. PLoS One (2013) 1.13
Ex vivo differentiated endothelial and smooth muscle cells from human cord blood progenitors home to the angiogenic tumor vasculature. Cardiovasc Res (2004) 1.13
Marked activity of irinotecan and rapamycin combination toward colon cancer cells in vivo and in vitro is mediated through cooperative modulation of the mammalian target of rapamycin/hypoxia-inducible factor-1alpha axis. Clin Cancer Res (2009) 1.12
Synthesis, antitumor activity, and mechanism of action of benzo[a]pyrano[3,2-h]acridin-7-one analogues of acronycine. J Med Chem (2006) 1.12
Targeted agents for adjuvant therapy of colon cancer. Semin Oncol (2006) 1.12
Radiosensitization by Chir-124, a selective CHK1 inhibitor: effects of p53 and cell cycle checkpoints. Cell Cycle (2009) 1.11
The histone deacetylase inhibitor abexinostat induces cancer stem cells differentiation in breast cancer with low Xist expression. Clin Cancer Res (2013) 1.10
From chemotherapy to targeted therapy in adjuvant treatment for stage III colon cancer. Semin Oncol (2011) 1.07
Novel protein scaffolds as emerging therapeutic proteins: from discovery to clinical proof-of-concept. Trends Biotechnol (2012) 1.06
Molecular determinants of topoisomerase I poisoning by lamellarins: comparison with camptothecin and structure-activity relationships. J Med Chem (2005) 1.06
Adjuvant therapy for stage II and III colorectal cancer. Semin Oncol (2007) 1.05
Irofulven cytotoxicity depends on transcription-coupled nucleotide excision repair and is correlated with XPG expression in solid tumor cells. Clin Cancer Res (2004) 1.05
Simplified prognostic model in patients with oxaliplatin-based or irinotecan-based first-line chemotherapy for metastatic colorectal cancer: a GERCOR study. Oncologist (2011) 1.05
PARPs and the DNA damage response. Carcinogenesis (2012) 1.05
Direct inhibition of the DNA-binding activity of POU transcription factors Pit-1 and Brn-3 by selective binding of a phenyl-furan-benzimidazole dication. Nucleic Acids Res (2008) 1.04
Design of DNA minor groove binding diamidines that recognize GC base pair sequences: a dimeric-hinge interaction motif. J Am Chem Soc (2007) 1.02
Trabectedin and its C subunit modified analogue PM01183 attenuate nucleotide excision repair and show activity toward platinum-resistant cells. Mol Cancer Ther (2011) 1.02
Mitosis-specific MPM-2 phosphorylation of DNA topoisomerase IIalpha is regulated directly by protein phosphatase 2A. Biochem J (2007) 1.02
Influence of compound structure on affinity, sequence selectivity, and mode of binding to DNA for unfused aromatic dications related to furamidine. Biopolymers (2002) 1.00
Selective inhibition of topoisomerase I and various steps of spliceosome assembly by diospyrin derivatives. Mol Pharmacol (2004) 0.99
Mechanisms underlying resistance to cetuximab in the HNSCC cell line: role of AKT inhibition in bypassing this resistance. Int J Oncol (2011) 0.99
EGFR- and VEGF(R)-targeted small molecules show synergistic activity in colorectal cancer models refractory to combinations of monoclonal antibodies. Clin Cancer Res (2011) 0.98
Novel E-ring camptothecin keto analogues (S38809 and S39625) are stable, potent, and selective topoisomerase I inhibitors without being substrates of drug efflux transporters. Mol Cancer Ther (2007) 0.97
5-Fluorouracil and its active metabolite FdUMP cause DNA damage in human SW620 colon adenocarcinoma cell line. J Appl Toxicol (2009) 0.96
DNA minor groove induced dimerization of heterocyclic cations: compound structure, binding affinity, and specificity for a TTAA site. J Mol Biol (2010) 0.96
Lamellarin D: a novel pro-apoptotic agent from marine origin insensitive to P-glycoprotein-mediated drug efflux. Cancer Lett (2005) 0.95
Current status of adjuvant therapy for colon cancer. Gastrointest Cancer Res (2007) 0.95
Antitumor activity, X-ray crystal structure, and DNA binding properties of thiocoraline A, a natural bisintercalating thiodepsipeptide. J Med Chem (2007) 0.95
Targeting the DNA-binding activity of the human ERG transcription factor using new heterocyclic dithiophene diamidines. Nucleic Acids Res (2012) 0.95
Water-mediated binding of agents that target the DNA minor groove. J Am Chem Soc (2011) 0.94
DNA repair pathways involved in repair of lesions induced by 5-fluorouracil and its active metabolite FdUMP. Biochem Pharmacol (2009) 0.93
In vivo topoisomerase I inhibition attenuates the expression of hypoxia-inducible factor 1α target genes and decreases tumor angiogenesis. Mol Med (2012) 0.92
Topoisomerase I and II inhibitors control caspase-2 pre-messenger RNA splicing in human cells. Mol Cancer Res (2004) 0.92
Influence of irofulven, a transcription-coupled repair-specific antitumor agent, on RNA polymerase activity, stability and dynamics in living mammalian cells. J Cell Sci (2008) 0.91
Stage II and stage III colon cancer: treatment advances and future directions. Cancer J (2010) 0.90
Dual inhibition of PI3K/Akt signaling and the DNA damage checkpoint in p53-deficient cells with strong survival signaling: implications for cancer therapy. Cell Cycle (2007) 0.90
The evolution of adjuvant therapy in the treatment of early-stage colon cancer. Clin Colorectal Cancer (2011) 0.90
Down-regulation of DNA topoisomerase IIalpha leads to prolonged cell cycle transit in G2 and early M phases and increased survival to microtubule-interacting agents. Mol Pharmacol (2005) 0.90
F14512, a potent antitumor agent targeting topoisomerase II vectored into cancer cells via the polyamine transport system. Cancer Res (2008) 0.89
Novel benzopyridothiadiazepines as potential active antitumor agents. J Med Chem (2005) 0.89
Synthesis and biological study of a new series of 4'-demethylepipodophyllotoxin derivatives. J Med Chem (2005) 0.89
Alkaloids from Cassytha filiformis and related aporphines: antitrypanosomal activity, cytotoxicity, and interaction with DNA and topoisomerases. Planta Med (2004) 0.89
Characterizations of irofulven cytotoxicity in combination with cisplatin and oxaliplatin in human colon, breast, and ovarian cancer cells. Cancer Chemother Pharmacol (2005) 0.89
Marked activity of irofulven toward human carcinoma cells: comparison with cisplatin and ecteinascidin. Clin Cancer Res (2003) 0.87
Syntheses and antitumor targeting G1 phase of the cell cycle of benzoyldihydroisoquinolines and related 1-substituted isoquinolines. J Med Chem (2002) 0.87
DNA alkylation damage and autophagy induction. Mutat Res (2013) 0.86
Acquired irinotecan resistance is accompanied by stable modifications of cell cycle dynamics independent of MSI status. Int J Oncol (2013) 0.86
Platinum-sensitivity in metastatic colorectal cancer: towards a definition. Eur J Cancer (2013) 0.86
Synthesis of 3,5-bis(2-indolyl)pyridine and 3-[(2-indolyl)-5-phenyl]pyridine derivatives as CDK inhibitors and cytotoxic agents. Bioorg Med Chem (2008) 0.86
Syntheses and antiproliferative activities of 7-azarebeccamycin analogues bearing one 7-azaindole moiety. J Med Chem (2003) 0.85
Factors for hematopoietic toxicity of carboplatin: refining the targeting of carboplatin systemic exposure. J Clin Oncol (2010) 0.85
Novel stable camptothecin derivatives replacing the E-ring lactone by a ketone function are potent inhibitors of topoisomerase I and promising antitumor drugs. Mol Pharmacol (2007) 0.84
S49076 is a novel kinase inhibitor of MET, AXL, and FGFR with strong preclinical activity alone and in association with bevacizumab. Mol Cancer Ther (2013) 0.84
Stereospecific synthesis of 5-substituted 2-bisarylthiocyclopentane carboxylic acids as specific matrix metalloproteinase inhibitors. J Med Chem (2003) 0.84
The antitumor triazoloacridone C-1305 is a topoisomerase II poison with unusual properties. Mol Pharmacol (2004) 0.84
Covalent binding of antitumor benzoacronycines to double-stranded DNA induces helix opening and the formation of single-stranded DNA: unique consequences of a novel DNA-bonding mechanism. Mol Cancer Ther (2005) 0.83
Irinotecan resistance is accompanied by upregulation of EGFR and Src signaling in human cancer models. Curr Pharm Des (2013) 0.83
Synthesis and biological activity of sulfonamide derivatives of epipodophyllotoxin. J Med Chem (2004) 0.83
Design of novel antitumor DNA alkylating agents: the benzacronycine series. Curr Med Chem Anticancer Agents (2004) 0.83
Induction of apoptosis by the plant alkaloid sampangine in human HL-60 leukemia cells is mediated by reactive oxygen species. Eur J Pharmacol (2005) 0.83
Identification of a GαGβγ, AKT and PKCα signalome associated with invasive growth in two genetic models of human breast cancer cell epithelial-to-mesenchymal transition. Int J Oncol (2012) 0.82
Alkylation of guanine in DNA by S23906-1, a novel potent antitumor compound derived from the plant alkaloid acronycine. Biochemistry (2002) 0.82
Low level of baseline circulating VEGF-A is associated with better outcome in patients with vascular sarcomas receiving sorafenib: an ancillary study from a phase II trial. Target Oncol (2013) 0.82
Synthesis and cytotoxic activity of benzo[c][1,7] and [1,8]phenanthrolines analogues of nitidine and fagaronine. Bioorg Med Chem (2004) 0.82
Influence of G2 arrest on the cytotoxicity of DNA topoisomerase inhibitors toward human carcinoma cells with different p53 status. Acta Biochim Pol (2002) 0.82
Molecular determinants for DNA minor groove recognition: design of a bis-guanidinium derivative of ethidium that is highly selective for AT-rich DNA sequences. Biochemistry (2005) 0.82
Novel bicyclic oxazolone derivatives as anti-angiogenic agents. Bioorg Med Chem Lett (2002) 0.82
Induction of apoptosis in HL-60 leukemia and B16 melanoma cells by the acronycine derivative S23906-1. Biochem Pharmacol (2002) 0.82
The unusual monomer recognition of guanine-containing mixed sequence DNA by a dithiophene heterocyclic diamidine. Biochemistry (2014) 0.82